GlassScriptPhysician profile
Rajiv K Sood
NPI 1699738351
$62,418.36
in general payments reported to CMS, 2019-2025
44 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $963 · 2020: $792 · 2021: $899 · 2022: $976 · 2023: $2,281 · 2024: $32K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $41K · Travel and Lodging: $12K · Food and Beverage: $4,784 · Honoraria: $500 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $40,750.00 |
| Travel and Lodging | $12,475.27 |
| Food and Beverage | $4,784.22 |
| Honoraria | $500.00 |
| Education | $278.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avita Medical Americas, LLC | $52,537.35 | 2023-2025 | Recell, Cohealyx, Permeaderm |
| Kerecis Limited | $2,087.07 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Abbvie INC. | $1,338.68 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $995.23 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $967.07 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $733.38 | 2019-2024 | Xarelto, Spravato |
| Novo Nordisk INC | $587.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $448.76 | 2019-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.52 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $312.66 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $228.11 | 2019-2024 | |
| Astellas Pharma US INC | $214.48 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $165.73 | 2022-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $151.37 | 2019-2024 | Camzyos, Eliquis |
| Sumitomo Pharma America, INC. | $115.16 | 2023-2025 | Gemtesa |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.